Recurrent gene fusions in breast cancer
OwnerArul M. Chinnaiyan, Chandan Kumar-Sinha +2inventors
InventorsArul M. Chinnaiyan, Chandan Kumar-Sinha, Dan Robinson, Shanker Kalyana-Sundaram
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for breast cancer.
Claims14
A kit for detecting gene fusions associated with cancer a subject, consisting essentially of at least a first gene fusion informative reagent for identification of a gene fusion selected from the group consisting of:
- ZNF700MAST1, NFIX-MAST1, ARID1A-MAST2, TADA2A-MAST1, GPBP1L1-MAST2, SEC16A-NOTCH1, SEC22B-NOTCH2, NOTCH1-GABRR2, NOTCH1-ch9:138722833, NOTCH1-SNHG7, NOTCH2-SEC22b, FGFR2-AFF3, CIT-ETV76, PEX5-ETV6, GTF2I-ETV7, BCL2L14-ETV6, ETV-CD70, ETV6-SYN1, CTNNA1-JMJD1B and RB1CC1-JAK1.
A method for identifying cancer in a patient comprising:
- (a) contacting a biological sample form a subject with a nucleic acid or polypeptide detection assay comprising:
- at least a first gene fusion informative reagent for identification of a gene fusion selected from the group consisting of:
- ZNF700-MAST1, NFIX-MAST1-ARID1A-MAST2, TADA2A-MAST1, GPBP1L1-MAST2, SEC16A-NOTCH1, SEC22B-NOTCH2, NOTCH1-GABRR2, NOTCH1-ch9:138722833, NOTCH1-SNHG7, NOTCH2-SEC22b, FGFR2-AFF3, CIT-ETV6, PEX5-ETV6, GTF2I-ETV7, BCL2L14-ETV6, ETV-CD70, ETV6-SYN1, CTNNA1-JMJD1B and RB1CC1-JAK1;
- and
- (b) identifying cancer in said subject when said gene fusion is present in said sample.
Dependencies are inferred from the claim text.